Without any discussion of evidence, this story makes big claims that border on disease-mongering.
The release should have mentioned how long recovered patients were followed and been a bit more transparent about financial matters, including patents on the drug.
This release offers a good summary along with mentioning the need for a larger study to confirm the findings.
The release is transparent about potential conflicts of interest and provides a good snapshot of the benefits. The release would have been better if it dialed back on the sensational language and included the cost of this pricey drug.